NCT03597581 2025-04-03
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Inspirna, Inc.
Phase 1 Completed
Inspirna, Inc.
Bristol-Myers Squibb
Fujian Cancer Hospital
Chung-Ang University
SWOG Cancer Research Network
Yonsei University
Yale University
University of Chicago